



ASO VISUAL ABSTRACT

ASO Visual Abstract: Oncologic Components of HIPEC—Key Question

In Patients with Gastric or Colorectal Adenocarcinoma Metastatic to the Peritoneum, Does Cytoreductive Surgery (CRS) plus Hyperthermic Intraperitoneal Perfusion with Chemotherapy (HIPEC) Prolong Survival or Increase the Risk of Complications Relative to CRS Alone?

Michael G. White, MD, MSc, and Brian Badgwell, MD, MS

Department of Surgical Oncology, Unit 1484, The University of Texas MD Anderson Cancer Center, Houston, TX

Current evidence does not support HIPEC with oxaliplatin for CRS patients with colorectal cancer carcinomatosis, and further studies are required to clarify

the role of other HIPEC regimens. Data do support CRS plus HIPEC in patients with gastric cancer carcinomatosis (<https://doi.org/10.1245/s10434-021-11253-x>).

